Newron Pharmaceuticals SpA (NWRN) AI Stock Analysis

• Market Cap: CHF145.52M
• Dividend Yield: N/A
• Average Volume (3M): 38.07K
• Price to Earnings (P/E): 10.4
• Beta (1Y): 1.45
• Revenue Growth: 450.19%
• EPS Growth: N/A
• Country: CH
• Employees: 22
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.71
• Shares Outstanding: 19,960,995
• 10 Day Avg. Volume: 26,668
• 30 Day Avg. Volume: 38,070
• PEG Ratio: 0.71
• Price to Book (P/B): -5.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -14.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 68 Neutral
• Price Target: CHF8.50 ▲(16.76%Upside)

Newron Pharmaceuticals SpA's overall stock score is driven by significant revenue growth and improved profitability, providing a strong foundation. However, high financial leverage and negative cash flow pose risks that could impact long-term stability. The stock's technical indicators show a positive trend, reflecting potential short-term gains. Valuation suggests it is attractively priced, but the lack of a dividend could be a drawback for some investors.

Newron Pharmaceuticals SpA Business Overview & Revenue Model

Company Description

Newron Pharmaceuticals SpA (NWRN) is a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous systems. Headquartered in Bresso, Italy, the company is engaged in the research and development of pharmaceutical products targeting neurological and psychiatric disorders. Newron's core product pipeline includes innovative treatments for conditions such as Parkinson's disease, schizophrenia, and rare diseases characterized by pain and inflammation.

How the Company Makes Money

Newron Pharmaceuticals SpA primarily generates revenue through the development and commercialization of its proprietary pharmaceutical products. The company's revenue model is based on securing licensing agreements and partnerships with larger pharmaceutical companies for the development and marketing of its drug candidates. These collaborations often involve upfront payments, milestone payments upon achieving specific development or regulatory milestones, and royalties on sales of successfully commercialized products. Additionally, Newron may receive research grants and funding to support its drug development programs, contributing to its overall revenue.

Newron Pharmaceuticals SpA Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
6.97M	9.06M	6.09M	5.76M	5.26M	7.04M
	Gross Profit
6.97M	9.06M	6.09M	5.76M	4.96M	5.61M
	EBIT
-15.01M	-11.63M	-13.30M	-12.36M	-18.07M	-20.90M
	EBITDA
-14.88M	-11.83M	-13.32M	-12.31M	-17.99M	-20.85M
	Net Income Common Stockholders
-18.83M	-16.22M	-17.49M	-14.90M	-21.00M	-20.21M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
39.16M	12.60M	22.77M	34.59M	31.25M	39.16M
	Total Assets
60.29M	25.87M	37.20M	50.49M	51.20M	60.29M
	Total Debt
16.89M	48.41M	45.66M	43.08M	26.34M	16.89M
	Net Debt
-5.17M	42.08M	32.24M	18.06M	13.13M	-5.17M
	Total Liabilities
23.49M	55.77M	51.23M	47.38M	33.95M	23.49M
	Stockholders Equity
36.80M	-29.91M	-14.03M	3.11M	17.25M	36.80M
Cash Flow		Free Cash Flow
-13.38M	-10.15M	-11.11M	-11.46M	-15.62M	-22.03M
	Operating Cash Flow
-13.37M	-10.14M	-11.09M	-11.45M	-15.59M	-21.98M
	Investing Cash Flow
5.27M	3.25M	-317.00K	8.42M	-616.00K	-932.00K
	Financing Cash Flow
8.28M	-192.00K	-186.00K	14.83M	7.37M	17.34M

Newron Pharmaceuticals SpA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:NWRN, the sentiment is Negative. The current price of 7.28 is below the 20-day moving average (MA) of 7.78, below the 50-day MA of 7.45, and below the 200-day MA of 8.20, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 41.47 is Neutral, neither overbought nor oversold. The STOCH value of 3.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:NWRN.

Newron Pharmaceuticals SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	72 Outperform	CHF557.64M	7.24		―	32.30%	631.04%
NWRN	68 Neutral	CHF145.52M	10.37		―	450.19%	―
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%
IDIA	51 Neutral	CHF382.17M	―		―	11.61%	-356.20%
MOLN	50 Neutral	CHF121.12M	―	-40.40%	―	-66.82%	4.14%
SANN	44 Neutral	$127.16M	2.58	-93.91%	―	-62.17%	-166.33%

Newron Pharmaceuticals SpA Corporate Events

Newron Pharmaceuticals Advances Phase III Program for Schizophrenia Treatment

Newron Pharmaceuticals has received approval for its pivotal Phase III development program ENIGMA-TRS, which will evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). This program, consisting of two studies, aims to meet regulatory requirements for marketing authorization in major markets like the USA and Europe. The approval marks a significant step for Newron, potentially enhancing its market position by addressing the unmet medical need for effective TRS treatments. The studies will assess the efficacy, tolerability, and safety of Evenamide, with patient recruitment starting immediately and results expected in late 2026.

Newron Pharmaceuticals Advances Phase-III Trials for Schizophrenia Treatment

Newron Pharmaceuticals announced the approval of its pivotal Phase-III development program ENIGMA-TRS, which includes two studies to evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). The studies, ENIGMA-TRS 1 and ENIGMA-TRS 2, aim to address the unmet medical need for effective treatments in TRS patients by targeting the glutamatergic system, offering a new therapeutic option for those who do not respond adequately to current antipsychotics.

New Leadership and Strategic Financial Moves at Newron Pharmaceuticals

Newron Pharmaceuticals announced the election of Dr. Chris Martin as the new Chairman of the Board during their 2025 General Meeting. The meeting also extended a capital increase until 2028, although some agenda items were not voted on due to a lack of quorum. This leadership change and financial strategy adjustment may influence Newron’s future operations and strategic direction, especially in the context of their ongoing drug development efforts.

Newron Pharmaceuticals Reports Strong 2024 Results and Strategic Growth Plans for 2025

Newron Pharmaceuticals reported significant progress in 2024, highlighted by promising data from studies on Evenamide, a potential treatment for schizophrenia. The company secured strategic licensing agreements with EA Pharma and Myung In Pharm, enhancing its market presence in Asia and supporting its upcoming Phase III study. With a net profit of EUR 15.8 million, Newron is poised for further growth in 2025, driven by its robust financial position and strategic partnerships.

Newron Pharmaceuticals Reports Profit and Strategic Advances in 2024

Newron Pharmaceuticals reported a net profit of EUR 15.8 million for 2024, a significant turnaround from the previous year’s loss, driven by licensing revenues from agreements with EA Pharma/Eisai Group and Myung In Pharm. The company has strengthened its financial position and expanded its market reach through strategic partnerships and capital measures, positioning itself for further growth in 2025 with plans to advance Evenamide’s development and potentially register its shares in the USA.